- Home
- UWMC vs EYPT Comparison
UWMC vs EYPT Comparison
Compare UWMC & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UWMC | EYPT |
|---|---|---|
| Founded | 1986 | 1987 |
| Country | United States | United States |
| Employees | 9100 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | UWMC | EYPT |
|---|---|---|
| Price | $3.40 | $13.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $6.13 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 13.3M | 786.4K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 11.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.60 | $3,115.57 |
| P/E Ratio | $82.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.27 | $5.46 |
| 52 Week High | $7.14 | $19.11 |
Technical Indicators
Market Signals| Indicator | UWMC | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 38.37 | 47.47 |
| Support Level | N/A | $12.66 |
| Resistance Level | $4.01 | $14.54 |
| Average True Range (ATR) | 0.20 | 0.75 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 14.01 | 39.81 |
Price Performance
Historical ComparisonAbout UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.